All In Biotech

NDA 215151 · Phathom

Voquezna

Vonoprazan Fumarate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Nov 1, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

132

24 Phase 3, 29 recruiting

FAERS reports

8,132

5,240 serious, 1,069 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2026.

VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. VOQUEZNA is a potassium-competitive acid blocker indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. ( 1 ) to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. ( 1 ) for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. ( 1 ) in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection in adults. ( 1 ) in combination with amoxicillin for the treatment of H. pylori infection in adults. ( 1 )

Mechanism: Vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of the gastric parietal cell through inhibition of the H + , K + -ATPase enzyme system in a potassium-competitive manner. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, in that it blocks the final step of acid production. Vonoprazan does not require activation by acid. Vonoprazan may selectively concentrate in the parietal cells in both the resting and stimulated states. Vonoprazan binds to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 1, 2023 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated NovelLetterLabelReview
2 products under this application
  • VOQUEZNA · VONOPRAZAN FUMARATE EQ 20MG BASE · TABLET, ORAL · Prescription
  • VOQUEZNA · VONOPRAZAN FUMARATE EQ 10MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vonoprazan" as an intervention, any sponsor and status, largest first.

All 132 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea526
  • off label use520
  • nausea485
  • drug ineffective457
  • gastrooesophageal reflux disease322
  • malaise317
  • decreased appetite272
  • headache271
  • pyrexia253
  • abdominal pain upper251
  • vomiting242
  • product dose omission issue232

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20111
20141
20152
201617
201741
201890
2019119
2020166
2021426
2022807
2023880
20241,448
20252,182
20261,951

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Voquezna (Vonoprazan Fumarate)

2024 spending

$31.3M

Beneficiaries

14,985

37,589 claims

Per beneficiary

$2,085

$20.76 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$46,258
2024$31,250,586

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 229 on PubMed

Sponsor: Phathom

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.